AKO Capital LLP recently announced the acquisition of new stake in Grifols S.A. (NASDAQ:GRFS). The institutional investor has increased its shareholding in the Healthcare company by 6.73% to 13.24 million shares with purchase of 0.84 million shares. This fresh investment now brings its stake to 5.07% valued currently at $250.67 million. In addition, Credit Suisse Securities (USA) LL. raised its holdings by 1.16 million to 13.24 million shares. And FIL Investment Advisors (UK) Ltd. has lifted its position by 0.27% or 32876.0 shares – to 12.29 million shares.
With over 0.74 million Grifols S.A. (GRFS) shares trading Tuesday and a closing price of $18.70 on the day, the dollar volume was approximately $13.92 million. The shares have shown a positive weekly performance of 0.32% and its price on 07/07/20 lost nearly -1.84%. Currently, there are 684.14M common shares owned by the public.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 6 analysts who have offered their price forecasts for GRFS have a consensus price objective of $32.09. The analysts have set the share’s price value over the next 12 months at a high of $38.78 and a low of $21.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Grifols S.A. stock is 1.70 for the next 12 months. The average price target is 30.09% above its last price level and an upside to the estimated low will see the stock gain 10.95% over that period. But an upside of 51.78% will see the stock hit the forecast high price target while mean target price for the stock is $36.50.
Insiders at the company have nil transactions over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC).
The top 3 mutual fund holders in Grifols S.A. are American Funds EuroPacific Growth, First Trust NYSE Arca Biotechnolo, and Fidelity Funds SICAV – European G. American Funds EuroPacific Growth owns 3.51 million shares of the company’s stock, all valued at over $66.51 million. The company sold 10428.0 shares recently to bring their total holdings to about 1.34% of the shares outstanding. First Trust NYSE Arca Biotechnolo has total holdings of 3.08 million shares valued at over $58.26 million and representing 1.18% of the shares outstanding. Fidelity Funds SICAV – European G bought 2550.0 shares to bring its total holdings to over 2.38 million shares at a value of $45.1 million. Fidelity Funds SICAV – European G now owns shares totaling to 0.91% of the shares outstanding.
Shares of Grifols S.A. (NASDAQ: GRFS) opened at $18.96, down -$0.09 from a prior closing price of $19.05. However, the script later closed the day at $18.70, down -1.84%. The company’s stock has a 5-day price change of 0.32% and -3.41% over the past three months. GRFS shares are trading -19.71% year to date (YTD), with the 12-month market performance down to -14.02% lower. It has a 12-month low price of $13.40 and touched a high of $25.73 over the same period. Currently, 0.74 million shares have been traded, compared to an average intraday trading volume of 1.02 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -2.58%, -4.75%, and -12.04% respectively.
Institutional ownership of Grifols S.A. (NASDAQ: GRFS) shares accounts for 53.68% of the company’s 684.14M shares outstanding. Mutual fund holders own 19.31%, while other institutional holders and individual stakeholders account for 29.95% and — respectively.
It has a market capitalization of $12.79B. The stock’s trailing 12-month PE ratio is 31.19, while the earnings-per-share (ttm) stands at $0.60. The company has a PEG of 2.76. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.87% over the week and 2.74% over the month.
Analysts forecast that Grifols S.A. (GRFS) will achieve an EPS of $0.38 for the current quarter, $0.37 for the next quarter and $1.53 for 2021. The lowest estimate earnings-per-share for the quarter is $0.38 while analysts give the company a high EPS estimate of $0.38. Comparatively, EPS for the current quarter was $0.34 a year ago. Earnings per share for the fiscal year are expected to increase by 16.90%, and 10.90% over the next financial year. EPS should grow at an annualized rate of 11.30% over the next five years, compared to 2.78% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 6 brokerage firm advisors rate Grifols S.A. (GRFS) as a “Strong Buy” at a consensus score of 1.70. Specifically, 3 Wall Street analysts polled rate the stock as a buy, while 2 of the 6 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the GRFS, a number of firms have released research notes about the stock. HSBC Securities stated their Hold rating for the stock in a research note on June 09, 2020. Citigroup coverage for the Grifols S.A. (GRFS) stock in a research note released on June 09, 2020 offered a Sell rating with a price target of. Citigroup was of a view on March 25, 2020 that the stock is Neutral, while JP Morgan gave the stock Overweight rating on June 27, 2019. Berenberg on their part issued Hold rating on February 08, 2019.